Abstract: Objective  To evaluate the efficacy， safety and pharmacoeconmics between pegaspargase(PEGasp) and Lsparaginase(Lasp)  in treatment of Chinese children with acute lymphoblasfic leukemia. Methods  CNKI， Wanfang， VIP， PubMed and OVID databases were searched to collect RCTs which compared PEGasp with Lasp in treatment of Chinese children with acute lymphoblasfic leukemia， and the retrieval time was until March， 2017. Metaanalysis was conducted by Revman 5.3 software. Results  Finally， five RCTs were included in this study. A total of 544 children with ALL were enrolled， including 272 patients in PEGasp group and 272 patients in Lasp group. ①The metaanalysis showed that the complete remission CR) rate and the total response (RR) rate between the two therapy groups were similar. Compared to Lasp group， the OR of the CR rate of PEGasp group was 0.85 (95%CI=0.551.34，P＞0.05); and the RR of the CR rate was 1.35 (95%CI=0.632.90，P＞0.05). ② All five articles reported the occurrence of adverse reaction. In each study，  the occurrence rate of adverse reaction between the two therapy groups was no statistically significant difference. ③In three articles， the hospitalized days and the number of drugs between the two therapy groups were compared. The metaanalysis of the hospitalized days between the two therapy groups showed that the hospitalized days of  PEGasp group was significantly shorter than that in Lasp group (WMD: -6.60， 95%CI=-7.99   to  -5.22). Conclusion  The effectiveness of PEGasp and Lasp in treatment of pediatric ALL is similar and has no difference in adverse effect. However， PEGasp may be a better choice from the point of view of pharmacoeconmics.

Key words: leukemia, lymphoid；chidlren; , pegaspargase, metaanalysis